Peptide Synthesis Market Size, Share, Trends, Industry Analysis Report

Recent Developments in Peptide Synthesis Domain

• In September 2025, PolyPeptide announced a significant milestone in its strategic expansion project in Malmö, Sweden, with the installation of new manufacturing modules. This initiative is a key part of the company's mid-term strategy to double the site's solid-phase peptide synthesis (SPPS) capacity.
• In August 2025, Cambrex announced the expansion of its API facility in Waltham, Massachusetts, to advance the development and manufacturing of peptide therapies. The expansion included a new GMP manufacturing suite, which has increased the facility's footprint by 20% and enables it to support peptide projects from development to manufacturing using solid-phase (SPPS), liquid-phase (LPPS), or hybrid synthesis approaches.
• In August 2025, Hybio Pharmaceutical signed a commercial manufacturing and supply agreement with Sunshine Mandi Pharmaceutical. Under the agreement, Hybio will serve as the large-scale manufacturer for a Semaglutide weight-loss injection, leveraging its expertise in peptide manufacturing to ensure a stable supply for the product's market launch.
• In March 2025, CordenPharma entered into a multi-year strategic partnership with Viking Therapeutics to support the commercial demand for their GLP-1 / GIP drug candidate, VK2735. Under this agreement, CordenPharma will provide end-to-end support, including the peptide API manufacturing, sterile fill-finish, and oral solid dosage drug product services.

Peptide Synthesis Market Trends

• Partnerships and Collaborations: The contract manufacturers involved in peptide synthesis domain have forged several partnerships with other stakeholders in order to enhance their service portfolios. The rising partnership activity in this domain is indicative of the growing preference for outsourcing manufacturing operations. This trend was particularly evident in 2025, with contract manufacturers signing a number of agreements. Notable agreements announced during the year include the product development and manufacturing agreement signed between Hybio Pharmaceutical and iCarbonX Intelligent Peptide (July 2025), and the acquisition of Senn Chemicals by Granules India to enter the peptide CDMO market (April 2025).
• Adoption of Green Chemistry Principles: The growing push for sustainability in peptide synthesis, driven by the adoption of greener solvents, solvent recycling, and energy-efficient processes, is significantly reducing the industry's environmental footprint, marking this as a critical innovation for the future of pharmaceutical manufacturing. This trend is particularly evident in the manufacturing of high-volume peptides, such as GLP-1 agonists. For instance, in March 2025, Innovate UK announced an investment of EUR 913,659 for a project led by Constructive Biology aimed at developing a more sustainable method for biomanufacturing of these weight-loss drugs. This trend is also reflected in the increasing number of strategic partnerships aimed at developing and integrating green chemistry solutions in peptide synthesis processes. In January 2025, EUROAPI announced collaboration with French CRO StrainChem, to gain access to their Sustainable Liquid Phase Peptide Synthesis (SLiPPS) proprietary technology.
• Process Optimization in Peptide Manufacturing: This represents a key market trend in the peptide synthesis industry, reflecting rapid innovation across manufacturing processes to enhance efficiency and purity. The industry is driving this innovation by refining core methods such as solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) while also adopting novel hybrid approaches and microwave-assisted technologies for more complex peptides.
• Impact of AI on Peptide Synthesis: The AI-driven advancements in peptide drug discovery and real-time process optimization, along with integration into automated synthesis platforms, will accelerate the discovery and manufacturing of novel therapeutics, marking this a critical growth factor in the future of peptide therapeutics.

Industry Experts on Peptide Synthesis Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Founder and Owner, Small Company, Germany
• Chief Financial Officer, Small Company, Germany
• Chief Business Officer, Small Company, US
• Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
• Vice President, Peptides, Large Company, Ireland
• Senior Manager, Peptide Business Project Leader, Large Company, Japan
• Chief Scientific Officer, Co-Founder, Small Company, India

Industry experts believe that the peptide synthesis market is facing significant manufacturing capacity shortage as demand for complex therapeutics rapidly outpaces the current global supply.

In May 2025, following the announcement of a significant investment of over €900 million into its peptide manufacturing capabilities, CordenPharma CEO & President, Dr. Michael Quirmbach, stated: “The peptide space is currently experiencing an explosion in demand, primarily driven by innovative molecules aimed at treating diabetes and obesity. These peptides are complex to manufacture, and there is a clear shortage of manufacturing capacity globally".

Peptide Synthesis Market Drivers

• Rising Prevalence of Chronic Diseases: The increasing global prevalence of chronic diseases, such as cancer and metabolic disorders, has intensified the demand for more targeted and effective peptide-based therapies. This growing therapeutic need fuels a larger and more complex R&D pipeline, resulting in drug developers outsourcing API production to specialized CDMOs for clinical and commercial supply.
• Technological Advancements in Peptide Synthesis: Continuous advancements in peptide synthesis technologies are improving the efficiency, scalability, and cost-effectiveness of producing complex molecules. These innovations enable contract manufacturing organizations (CMOs) to tackle more challenging projects, making it more feasible for drug developers to outsource the production of next-generation peptide therapeutics.

Market Segmentation Analysis

Solid Phase Synthesis to be the Cornerstone of Peptide Synthesis

• Based on the type of chemical synthesis method, the global market is segmented into solid phase synthesis, liquid phase synthesis, and hybrid phase synthesis. According to the peptide synthesis market report, the solid phase synthesis method segment holds around 50% of the overall market share. This dominance stems the numerous advantages of solid phase synthesis method, including rapid production of linear peptides, simplified purification, and cost-effectiveness.
• It is important to highlight here that hybrid phase synthesis segment is likely to grow at a higher CAGR (7.2%). This growth is primarily attributed to its unique suitability for the complex and long peptide sequences entering the R&D pipeline. By combining the strengths of both SPPS and LPPS, this approach offers optimal efficiency, yield, and cost-effectiveness for next-generation therapeutics that are difficult to manufacture using a single method alone.

Commercial Scale Manufacturing to Retain Dominant Share

• Based on the different scales of operation, the global market is segmented into commercial scale, and preclinical / clinical scale. According to the peptide synthesis market forecast, the commercial scale segment accounts for over 90% of the overall market share.
• It is important to highlight that commercial scale segment will remain dominant in the future and is likely to grow at a higher CAGR. This considerable peptide synthesis market size is mainly due to the substantial volumes and high monetary value associated with manufacturing GMP-grade peptide APIs. Long-term commercial supply agreements for marketed therapies generate revenue that significantly surpasses the preclinical and clinical scale projects.

Regional Insights

Europe Dominates the Market for Peptide Synthesis

According to our peptide synthesis market analysis, Europe is dominating the market by securing around 40% of the overall revenue share. This dominance is likely to be the result of the region's significant share of global manufacturing capacity, a higher number of clinical trials in the region, and a robust innovation ecosystem built on strong academic-industry collaborations.

Belgium Peptide Synthesis Market

Belgium is dominating the peptide synthesis market, supported by its status as a major European biotech hub, government incentives for the life sciences, and a high concentration of biopharmaceutical research. The country’s central strategic location for pharmaceutical logistics and its network of specialized manufacturing facilities further enhance market growth, making Belgium an essential contributor to the European peptide supply chain.

Switzerland Peptide Synthesis Market

Switzerland is emerging as a key market for peptide synthesis, primarily due to the presence of major global pharmaceutical companies, leading contract manufacturers, and academic research institutions. The nation's significant investment in biotechnology and a deeply integrated life sciences ecosystem further accelerates innovation in this country.

Peptide Synthesis Market Growth in Asia Pacific and North American Region

Asia Pacific is expected to witness a higher CAGR, primarily driven by its rapidly expanding regional pharmaceutical market, significant government investment in life sciences, and a cost-effective manufacturing ecosystem characterized by lower capital expenditure and inexpensive skilled labor. This growth is being supported by the expanding capabilities of regional manufacturers, such as STA Pharmaceutical, a WuXi AppTec company, Hybio Pharmaceuticals, Piramal Pharma Solutions, and PeptiStar.

North America is growing steadily due to its mature pharmaceutical industry, a well-established ecosystem of biotechnology firms driving research. This growth is also being supported by a growing focus on domestic production, driven by concerns over potential US tariffs on imported pharmaceuticals, which is encouraging investment in local peptide API manufacturing. This trend is highlighted by recent moves, such as Cambrex's expansion of its peptide manufacturing capabilities in the US.

Peptide Synthesis Market: Scope of the Report

Market Segments

Based on the research, we have segmented the Peptide Synthesis Market into type of API, type of peptide synthesis method, type of chemical synthesis method, scale of operation, company size and geographical regions.

By Type of API

• Generic APIs
• New Chemical Entities

By Type of Peptide Synthesis Method

• Chemical Synthesis
• Non-Chemical Synthesis

By Type of Chemical Synthesis Method

• Solid Phase Synthesis
• Liquid Phase Synthesis
• Hybrid Phase Synthesis

By Scale of Operation

• Commercial Scale
• Preclinical / Clinical Scale

By Company Size

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

By Geographical Regions

• North America
  • US
  • Canada
• Europe
  • Belgium
  • Switzerland
  • UK
  • Germany
  • Ireland
  • Netherlands
  • Italy
  • France
  • Sweden
  • Rest of Europe
• Asia-Pacific and Rest of the World
  • China
  • India
  • Japan
  • Korea
  • Rest of Asia-Pacific and Other Countries